Arrowhead Pharmaceuticals, Inc.
ARWRNASDAQHealthcare● Active
$73.86
+$0.77(+1.05%)
Market Cap$10.4B
P/E Ratio—
52W High$82.26
52W Low$14.3
Arrowhead Pharmaceuticals, Inc. (ARWR) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ARWR · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.03B | ($0.61B) | ($0.21B) | ($0.18B) | ($0.14B) |
| Depreciation & Amort. | $0.02B | $0.02B | $0.01B | $0.01B | $0.01B |
| Stock-Based Comp. | $0.06B | $0.07B | $0.08B | $0.12B | $0.08B |
| Change in Working Capital | ($0.02B) | $0.03B | ($0.05B) | ($0.10B) | $0.23B |
| Net Cash from Operations | $0.18B | ($0.46B) | ($0.15B) | ($0.14B) | $0.17B |
| Investing Activities | |||||
| Capital Expenditure | ($0.02B) | ($0.14B) | ($0.18B) | ($0.05B) | ($0.02B) |
| Purchases of Investments | ($0.80B) | ($0.72B) | ($0.25B) | ($0.22B) | ($0.24B) |
| Sales of Investments | $0.69B | $0.44B | $0.33B | $0.27B | $0.12B |
| Net Cash from Investing | ($0.13B) | ($0.42B) | ($0.10B) | ($0.01B) | ($0.14B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.19B) | $0.39B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.07B | $0.87B | $0.25B | $0.07B | $0.01B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.16B | ($0.60B) | ($0.33B) | ($0.19B) | $0.15B |
| FCF Margin %(computed) | 18.91% | — | -137.34% | -77.67% | 106.84% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Arrowhead Pharmaceuticals, Inc. data
About Arrowhead Pharmaceuticals, Inc. (ARWR) Cash Flow Statement
Arrowhead Pharmaceuticals, Inc. generated operating cash flow of $0.18B and free cash flow of $0.16B for 2025 — a FCF margin of 18.91%. Capital expenditure was ($0.02B).
Frequently asked questions
ARWR · 4 questionsArrowhead Pharmaceuticals, Inc. generated free cash flow of $0.16B for 2025, up 126.0% year-over-year.
ARWR free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10